In this episode of “Insight Exchange,” we explore the crucial role of Scope 3 emissions reduction in the pharmaceutical industry. Listen to L.E.K. Consulting experts Verena Ahnert and Max Cambras, who share their insights on the significance of Scope 3 emissions, the current state of commitments in pharma and how emissions reduction is both a strategic consideration and mutually beneficial to both pharma and the environment. Key points/topics covered: Explanation of Scope 3 emissions and their importance in pharma The current state of Scope 3 commitments in the pharmaceutical industry Key drivers of Scope 3 emissions in pharma The strategic co-benefits of Scope 3 emissions reduction in the pharmaceutical industry The path to achieving strategic co-benefits through emissions reduction in pharma Tune in for a deep dive into a pressing environmental issue that’s reshaping the pharma industry’s strategies and operations. Interested in learning more? Read our Special Report, Scope 3 Emissions: A Strategic Imperative for Pharma Companies. Connect with our experts on LinkedIn:Verena Ahnert, Partner, L.E.K. Consulting: https://www.linkedin.com/in/verena-ahnert-7a449a2/Max Cambras, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/max-cambras-08348411/ Visit L.E.K. Consulting at https://www.lek.com/